LUPRON DEPOT-PED KIT

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   Apr 14, 2023

   3 yr 3 mo ago

2. Exclusivity ends · NS

   New strength exclusivity (3 years)

   Apr 14, 2026

   2 mo ago

3. Today

4. Patent 9617303 expires

   Listed method-of-use patent (U-3611) expiration.

   Mar 22, 2028

   in 1 yr 9 mo

5. Patent 8921326 expires

   Listed drug product patent expiration.

   Feb 05, 2031

   in 4 yr 8 mo

Pharmaceutical detail

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

• FENSOLVI KITBrand (NDA)

  NDA 213150 · TOLMAR

  2020
• LEUPROLIDE ACETATE FOR DEPOT SUSPENSIONBrand (NDA)

  NDA 205054 · INVAGEN PHARMS

  2018
• ELIGARD KITBrand (NDA)

  NDA 021731 · TOLMAR

  2004
• ELIGARD KITBrand (NDA)

  NDA 021488 · TOLMAR

  2003
• ELIGARD KITBrand (NDA)

  NDA 021379 · TOLMAR

  2002
• ELIGARD KITBrand (NDA)

  NDA 021343 · TOLMAR

  2002
• VIADURBrand (NDA)

  NDA 021088 · ORTHO MCNEIL JANSSEN

  2000
• LUPRON DEPOTBrand (NDA)

  NDA 020708 · ABBVIE ENDOCRINE INC

  1997
• LUPRON DEPOTBrand (NDA)

  NDA 020517 · ABBVIE ENDOCRINE INC

  1995
• LUPRON DEPOTBrand (NDA)

  NDA 020011 · ABBVIE ENDOCRINE INC

  1990
• LUPRON DEPOTBrand (NDA)

  NDA 019732 · ABBVIE ENDOCRINE INC

  1989
• LUPRONBrand (NDA)

  NDA 019010 · ABBVIE ENDOCRINE INC

  1985

Marketing exclusivity (1)

• NSNew strength exclusivity (3 years)

  Apr 14, 2026

  2 mo ago

Listed patents (2)